Inhalable Drugs Market Size, Share & Trends Analysis Report By Drug Class (Aerosol, Dry Powder Formulation, Spray), By Application (Respiratory & Non-Respiratory Diseases), By Region, And Segment Forecasts, 2023

The global inhalable drugs market size is expected to reach over USD 52.4 billion by 2030., registering a CAGR of 6.6% from 2023 to 2030. Rising prevalence of respiratory diseases and increasing geriatric population are some of the key factors expected to drive the market. Chronic obstructive pulmonary disease (COPD) is a life-threatening respiratory ailments, which is projected to become the third leading cause of death globally. This will increase the demand for inhalable drugs.

According to the Global Burden of Disease study, in 2016, 251 million cases of COPD were reported worldwide. Hence, the need for developing new inhalable drugs has increased. For instance, in January 2019, Verona Pharma received WHO approval for developing Ensifentrine indicated for COPD, which has completed Phase II of clinical trials.

Advancements in inhalable drugs is anticipated to propel the inhalable drugsmarket. Nanoparticles are studied for the development of advanced inhalation drugs. For instance, in April 2019, a scientist from Queensland University of Technology conducted a research using chitosan nanoparticles loaded with inhalation powder for lung cancer. These nanoparticles can easily penetrate the lower respiratory tract and can diffuse into the bloodstream.

Rising prevalence of non-respiratory diseases such as diabetes and Parkinson’s diseases is also expected to drive the market. Therefore, manufacturers are developing cost-effective and innovative inhalable drugs. For instance, in January 2019, MannKind Corporation developed and commercialized Afrezza for diabetic patients.

Presence of strong pipeline drugs is considered to be one of the major factors estimated to boost the market growth. There are more than 220 ongoing projects under clinical trials globally. For instance, GlaxoSmithKline’s triple combination therapy of Fluticasone Furoate/Vilanterol/Umeclidinium Bromide to treat asthma is in Phase III and is likely to be launched during the forecast period.

Companies are undergoing strategic initiatives such as collaborations, mergers and acquisitions, partnerships, and awareness programs to widen their product portfolio and gain a stronger foothold in the market. For instance, in July 2019, Cipla, Inc. entered into a joint venture with Shanghai-based Jiangsu Acebright Pharmaceuticals to establish a company in the People’s Republic of China to manufacture respiratory products.

Inhalable Drugs Market Report Highlights

By product, the dry powder formulation segment dominated the market for inhalable drugs in 2022 owing to benefits such as low density and ability to disperse easily through inhalers
Based on application, respiratory diseases held the largest market share in terms of revenue in 2022, due to high prevalence of asthma and COPD. The non-respiratory diseases segment is growing at a rapid pace owing to the high opportunity in management of various neurological disorders
North America held the leading position in the global inhalable drugs market for inhalable drugs in 2022, driven by established pharmaceutical industry and healthcare facilities and growing awareness about the use of inhalers. The Asia Pacific market is projected to exhibit the fastest growth during the forecast period.
Key players in this industry include AstraZeneca; Vectura, Cipla Inc.; GlaxoSmithKline; Novartis; Mundipharma; Boehringer Ingelheim International GmbH; and Mylan.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.1.1. Drug Class
1.1.2. Application
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug class outlook
2.2.2. Application outlook
2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Inhalable Drugs Market Variables, Trends & Scope

3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Inhalable Drugs Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape

Chapter 4. Inhalable Drugs: Drug Class Estimates & Trend Analysis

4.1. Inhalable Drugs Market: Key Takeaways
4.2. Inhalable Drugs Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Aerosol
4.3.1. Aerosol market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Dry Powder Formulation
4.4.1. Dry powder formulation market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Spray
4.5.1. Spray market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Inhalable Drugs: Application Estimates & Trend Analysis

5.1. Inhalable Drugs Market: Key Takeaways
5.2. Inhalable Drugs Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Respiratory Diseases
5.3.1. Respiratory diseases market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Non-respiratory Diseases
5.4.1. Non-respiratory diseases market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Inhalable Drugs Market: Regional Estimates & Trend Analysis

6.1. Regional Outlook
6.2. Inhalable Drugs Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Denmark
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Sweden
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Norway
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. AstraZeneca
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Sanofi
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Vectura Group Ltd
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Viatris Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. GSK plc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Mundipharma International.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Boehringer Ingelheim International GmbH.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Cipla Inc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 3 North America inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 4 North America inhalable drugs market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 6 U.S. inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 7 Canada inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 8 Canada inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 9 Europe inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 10 Europe inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 11 Europe inhalable drugs market, by region, 2018 - 2030 (USD Million)
Table 12 Germany inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 13 Germany inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 14 UK inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 15 UK inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 16 France inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 17 France inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 18 Italy inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 19 Italy inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 20 Spain inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 21 Spain inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 22 Denmark inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 23 Denmark inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 24 Sweden inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 25 Sweden inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 26 Norway inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 27 Norway inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 28 Asia Pacific inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 29 Asia Pacific inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 30 Asia Pacific inhalable drugs market, by region, 2018 - 2030 (USD Million)
Table 31 Japan inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 32 Japan inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 33 China inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 34 China inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 35 India inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 36 India inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 37 Australia inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 38 Australia inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 39 Thailand inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 40 Thailand inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 41 South Korea inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 42 South Korea inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 43 Latin America inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 44 Latin America inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 45 Latin America inhalable drugs market, by region, 2018 - 2030 (USD Million)
Table 46 Brazil inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 47 Brazil inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 48 Mexico inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 49 Mexico inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 50 Argentina inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 51 Argentina inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 53 Middle East and Africa inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa inhalable drugs market, by region, 2018 - 2030 (USD Million)
Table 55 South Africa inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 56 South Africa inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 59 UAE inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 60 UAE inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 61 Kuwait inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 62 Kuwait inhalable drugs market, by Application, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Inhalable drugs: Market outlook
Fig. 9 Inhalable drugs: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Inhalable drugs market driver impact
Fig. 15 Inhalable drugs market restraint impact
Fig. 16 Inhalable drugs market strategic initiatives analysis
Fig. 17 Inhalable drugs market: Drug class movement analysis
Fig. 18 Inhalable drugs market: Drug class outlook and key takeaways
Fig. 19 Aerosol market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Dry powder formulation market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Spray market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Inhalable drugs market: Application movement analysis
Fig. 23 Inhalable drugs market: Application outlook and key takeaways
Fig. 24 Respiratory diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Non-respiratory diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Global inhalable drugs market: Regional movement analysis
Fig. 27 Global inhalable drugs market: Regional outlook and key takeaways
Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Companies Mentioned

AstraZeneca
Sanofi
Vectura Group Ltd
Viatris Inc.
GSK plc.
Mundipharma International.
Boehringer Ingelheim International GmbH.
Cipla Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	80
Published	September 2023
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 31.5 Billion
Forecasted Market Value ( USD ) by 2030	$ 52.4 Billion
Compound Annual Growth Rate	6.6%
Regions Covered	Global
No. of Companies Mentioned	8

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5842EUR$5,950USD£4,875GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6824EUR$6,950USD£5,694GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€8788EUR$8,950USD£7,332GBP

Inhalable Drugs Market Size, Share & Trends Analysis Report By Drug Class (Aerosol, Dry Powder Formulation, Spray), By Application (Respiratory & Non-Respiratory Diseases), By Region, And Segment Forecasts, 2023 - 2030

Inhalable Drugs Market Report Highlights

Table of Contents

Companies Mentioned

Methodology

Table Information

Inhalable Drugs Market Report Highlights

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Inhalable Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

Inhalable Drugs Market by Product, Application - Global Forecast 2025-2030

Inhalable Drugs Global Market Report 2024

Inhalable Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

Inhalable Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update